The Wnt signaling pathway: implications for therapy in osteosarcoma

References

• Hayden JB, Hoang BH. Osteosarcoma: basic science and clinical implications. Orthop. Clin. North. Am.37(1), 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med.314(25), 1600–1606 (1986).
   PubMed Web of Science ®Google Scholar
• Cleton-Jansen A-M, Anninga JK, Briaire-De Bruijn IH et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br. J. Cancer101(11), 1909–1918 (2009).
   PubMedGoogle Scholar
• Moon RT. Wnt/β-catenin pathway. Sci. STKE2005(271), (2005).
   Google Scholar
• Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma55(3), 165–176 (2008).
   PubMedGoogle Scholar
• Luo J, Chen J, Deng Z-L et al. Wnt signaling and human diseases: what are the therapeutic implications? Lab. Invest87(2), 97–103 (2007).
   PubMed Web of Science ®Google Scholar
• Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug. Discov.5(12), 997–1014 (2006).
   PubMed Web of Science ®Google Scholar
• Gong Y, Slee RB, Fukai N et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell107(4), 513–523 (2001).
   PubMed Web of Science ®Google Scholar
• Kato M, Patel MS, Levasseur R et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol.157(2), 303–314 (2002).
   PubMed Web of Science ®Google Scholar
• Babij P, Zhao W, Small C et al. High bone mass in mice expressing a mutant LRP5 gene. J. Bone Miner Res.18(6), 960–974 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. Curr. Opin. Rheumatol.19(4), 376–382 (2007).
   PubMed Web of Science ®Google Scholar
• Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J. Clin. Invest.116(5), 1202–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Haydon RC, Deyrup A, Ishikawa A et al. Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma. Int. J. Cancer102(4), 338–342 (2002).
   PubMed Web of Science ®Google Scholar
• Enomoto M, Hayakawa S, Itsukushima S et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene28(36), 3197–3208 (2009).
   PubMed Web of Science ®Google Scholar
• Hoang BH, Kubo T, Healey JH et al. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int. J. Cancer109(1), 106–111 (2004).
   PubMed Web of Science ®Google Scholar
• Mandal D, Srivastava A, Mahlum E et al. Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene386(1–2), 131–138 (2007).
   PubMed Web of Science ®Google Scholar
• Kansara M, Tsang M, Kodjabachian L et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest.119(4), 837–851 (2009).
   PubMed Web of Science ®Google Scholar
• Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/β-catenin pathway in conventional high-grade osteosarcoma. J. Pathol.220(1), 24–33 (2010).
   PubMed Web of Science ®Google Scholar
• Matushansky I, Hernando E, Socci ND et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J. Clin. Invest.117(11), 3248–3257 (2007).
   PubMed Web of Science ®Google Scholar
• Lin YC, You L, Xu Z et al. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem. Biophys. Res. Commun.341(2), 635–640 (2006).
   PubMed Web of Science ®Google Scholar
• Mazieres J, He B, You L et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res.64(14), 4717–4720 (2004).
   PubMed Web of Science ®Google Scholar
• Batra S, Shi Y, Kuchenbecker KM et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem. Biophys. Res. Commun.342(4), 1228–1232 (2006).
   PubMedGoogle Scholar
• Ai L, Tao Q, Zhong S et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis27(7), 1341–1348 (2006).
   PubMed Web of Science ®Google Scholar
• Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2’-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci.97(1), 64–71 (2006).
   PubMed Web of Science ®Google Scholar
• Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol. Cancer Ther.9(3), 731–741 (2010).
   PubMedGoogle Scholar
• Guo Y, Xie J, Rubin E et al. Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res.68(9), 3350–3360 (2008).
   Google Scholar
• DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, Rubinfeld B. The soluble Wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res.67(11), 5371–5379 (2007).
   PubMed Web of Science ®Google Scholar
• Monaghan H, Bubb VJ, Sirimujalin R, Millward-Sadler SJ, Salter DM. Adenomatous polyposis coli (APC), β-catenin, and cadherin are expressed in human bone and cartilage. Histopathology39(6), 611–619 (2001).
   PubMed Web of Science ®Google Scholar
• Hoang BH, Kubo T, Healey JH et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway. Cancer Res.64(8), 2734–2739 (2004).
   PubMed Web of Science ®Google Scholar
• Fedi P, Bafico A, Nieto Soria A et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J. Biol. Chem.274(27), 19465–19472 (1999).
   PubMed Web of Science ®Google Scholar
• Guo Y, Zi X, Koontz Z et al. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J. Orthop. Res.25(7), 964–971 (2007).
   PubMed Web of Science ®Google Scholar
• Guo Y, Rubin EM, Xie J, Zi X, Hoang BH. Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin. Orthop. Relat. Res.466(9), 2039–2045 (2008).
   PubMed Web of Science ®Google Scholar
• van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development (Cambridge, England)136(19), 3205–3214 (2009).
   PubMed Web of Science ®Google Scholar
• Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits β-catenin–TCF signaling depending on receptor context. PLoS Biol.4(4), e115 (2006).
   PubMed Web of Science ®Google Scholar
• Oishi I, Suzuki H, Onishi N et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells8(7), 645–654 (2003).
   PubMed Web of Science ®Google Scholar
• Morioka K, Tanikawa C, Ochi K et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci.100(7), 1227–1233 (2009).
   PubMed Web of Science ®Google Scholar
• Nagayama S, Katagiri T, Tsunoda T et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res.62(20), 5859–5866 (2002).
   PubMed Web of Science ®Google Scholar
• Nagayama S, Fukukawa C, Katagiri T et al. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene24(41), 6201–6212 (2005).
   PubMed Web of Science ®Google Scholar
• Fukukawa C, Nagayama S, Tsunoda T, Toguchida J, Nakamura Y, Katagiri T. Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma. Oncogene28(8), 1110–1120 (2009).
   PubMed Web of Science ®Google Scholar
• Coltella N, Manara MC, Cerisano V et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J.17(9), 1162–1164 (2003).
   PubMed Web of Science ®Google Scholar
• Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res.62(18), 5126–5128 (2002).
   PubMed Web of Science ®Google Scholar
• Patanè S, Avnet S, Coltella N et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res.66(9), 4750–4757 (2006).
   PubMed Web of Science ®Google Scholar
• Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest. New Drugs23(5), 391–409 (2005).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology69(Suppl. 3), 46–56 (2005).
   PubMed Web of Science ®Google Scholar
• Albanell J, Gascon P. Small molecules with EGFR-TK inhibitor activity. Curr. Drug Targets6(3), 259–274 (2005).
   PubMedGoogle Scholar
• Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur. J. Cancer46(7), 1260–1270 (2010).
   PubMed Web of Science ®Google Scholar
• Liao AT, McCleese J, Kamerling S, Christensen J, London CA. A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma. Vet. Comp. Oncol.5(3), 177–196 (2007).
   Google Scholar
• McCleese JK, Bear MD, Fossey SL et al. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int. J. Cancer125(12), 2792–2801 (2009).
   PubMed Web of Science ®Google Scholar
• Regenbrecht CR, Lehrach H, Adjaye J. Stemming cancer: functional genomics of cancer stem cells in solid tumors. Stem. Cell Rev.4(4), 319–328 (2008).
   PubMed Web of Science ®Google Scholar
• Gibbs CP, Kukekov VG, Reith JD et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia7(11), 967–976 (2005).
   PubMed Web of Science ®Google Scholar
• Wang L, Park P, Zhang H, La Marca F, Lin C-Y. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int. J. Cancer128(2), 294–303 (2010).
   Google Scholar
• Tirino V, Desiderio V, d’Aquino R et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One3(10), e3469 (2008).
   PubMed Web of Science ®Google Scholar
• Levings PP, McGarry SV, Currie TP et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res.69(14), 5648–5655 (2009).
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature432(7015), 396–401 (2004).
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature445(7123), 111–115 (2007).
   PubMed Web of Science ®Google Scholar
• Honoki K, Fujii H, Kubo A et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol. Rep.24(2), 501–505 (2010).
   PubMed Web of Science ®Google Scholar
• Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med.10(1), 55–63 (2004).
   PubMed Web of Science ®Google Scholar
• Dravid G, Ye Z, Hammond H et al. Defining the role of Wnt/β-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. Stem Cells23(10), 1489–1501 (2005).
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res.16(12), 3153–3162 (2010).
   PubMed Web of Science ®Google Scholar
• Kaur J, Sanyal SN. PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumour Biol.31(6), 623–631 (2010).
   PubMed Web of Science ®Google Scholar
• Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med.348(10), 891–899 (2003).
   PubMed Web of Science ®Google Scholar
• Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol.3(3), 166–174 (2002).
   PubMed Web of Science ®Google Scholar
• Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med.348(10), 883–890 (2003).
   PubMed Web of Science ®Google Scholar
• Xia JJ, Pei LB, Zhuang JP et al. Celecoxib inhibits β-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J. Int. Med. Res.38(4), 1294–1304 (2010).
   Google Scholar
• Cui C, Zhang Y, Wang L, Liu H, Cui G. Enhanced anticancer activity of glutamate prodrugs of all-trans retinoic acid. J. Pharm. Pharmacol61(10), 1353–1358 (2009).
   PubMed Web of Science ®Google Scholar
• Shah S, Hecht A, Pestell R, Byers SW. Trans-repression of β-catenin activity by nuclear receptors. J. Biol. Chem.278(48), 48137–48145 (2003).
   PubMed Web of Science ®Google Scholar
• Park CH, Chang JY, Hahm ER, Park S, Kim H-K, Yang CH. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem. Biophys. Res. Commun.328(1), 227–234 (2005).
   PubMed Web of Science ®Google Scholar
• Kim J, Zhang X, Rieger-Christ KM et al. Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J. Biol. Chem.281(16), 10865–10875 (2006).
   PubMed Web of Science ®Google Scholar
• Jaiswal AS, Marlow BP, Gupta N, Narayan S. β-catenin-mediated transactivation and cell–cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene21(55), 8414–8427 (2002).
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Leleu X, Sacco A et al. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström’s macroglobulinemia. Clin. Cancer Res.14(6), 1849–1858 (2008).
   PubMed Web of Science ®Google Scholar
• Kakarala M, Brenner DE, Korkaya H et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat122(3), 777–785 (2010).
   PubMed Web of Science ®Google Scholar
• Lepourcelet M, Chen Y-NP, France DS et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell5(1), 91–102 (2004).
   PubMed Web of Science ®Google Scholar
• Trosset J-Y, Dalvit C, Knapp S et al. Inhibition of protein–protein interactions: the discovery of druglike β-catenin inhibitors by combining virtual and biophysical screening. Proteins64(1), 60–67 (2006).
   PubMed Web of Science ®Google Scholar
• Chen Z, Venkatesan AM, Dehnhardt CM et al. 2,4-diamino-quinazolines as inhibitors of β-catenin/Tcf-4 pathway: potential treatment for colorectal cancer. Bioorg Med. Chem. Lett.19(17), 4980–4983 (2009).
   PubMed Web of Science ®Google Scholar
• Grandy D, Shan J, Zhang X et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem.284(24), 16256–16263 (2009).
   PubMed Web of Science ®Google Scholar
• Shan J, Shi D-L, Wang J, Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry44(47), 15495–15503 (2005).
   PubMed Web of Science ®Google Scholar
• Fujii N, You L, Xu Z et al. An antagonist of dishevelled protein–protein interaction suppresses β-catenin-dependent tumor cell growth. Cancer Res.67(2), 573–579 (2007).
   PubMed Web of Science ®Google Scholar
• Emami KH, Nguyen C, Ma H et al. A small molecule inhibitor of β-catenin/CREB-binding protein transcription [corrected]. Proc. Natl Acad. Sci. USA101(34), 12682–12687 (2004).
   PubMed Web of Science ®Google Scholar
• He B, You L, Uematsu K et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia6(1), 7–14 (2004).
   PubMed Web of Science ®Google Scholar
• Brown AM. Canonical Wnt signaling: high-throughput RNAi widens the path. Genome Biol.6(9), 231 (2005).
   Google Scholar